A 52-week, Randomised, Double Blind, Multicentre, 2-arm Parallel Group Trial Assessing Efficacy of CHF6001 (Total Daily Dose 3200μg) Dry Powder Inhaler (DPI) add-on to Maintenance Medium or High Dose of Inhaled Corticosteroids in Combination With Long-acting ß2-agonists in Subjects With Uncontrolled Asthma
Latest Information Update: 31 Mar 2025
At a glance
- Drugs Tanimilast (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms TANGO
- Sponsors Chiesi Farmaceutici SpA
Most Recent Events
- 28 Mar 2025 Planned End Date changed from 21 Mar 2026 to 21 Feb 2027.
- 28 Mar 2025 Planned primary completion date changed from 28 Feb 2025 to 28 Mar 2026.
- 28 Mar 2025 Status changed from recruiting to active, no longer recruiting.